MM · Oncology · 7 drugs · 6 indications
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|---|---|---|---|---|
| Cevostamab | ROG.SW | FcRH5 x CD3 T-cell engager | Bispecific | IV | PHASE3 |
| Ninlaro | — | Proteasome inhibitor | Small molecule | PO | APPROVED |
| Darzalex | GMAB | Anti-CD38 | Antibody | IV | APPROVED |
| Tecvayli | GMAB | BCMAxCD3 bispecific | Bispecific | SC | APPROVED |
| Talvey | GMAB | GPRC5DxCD3 bispecific | Bispecific | SC | APPROVED |
| Kyprolis | AMGN | Proteasome inhibitor | Small molecule | IV | APPROVED |
| Lynozyfic | REGN | BCMAxCD3 bispecific | Bispecific antibody | IV then SC | APPROVED |